Skip to main content
SpringerLink
Log in

Psychotomimetic Effects of Opioids

  • Chapter
Neurobiology of Opioids

Abstract

The attraction of opioids for over 2000 years and possibly the cause for their addictive properties are closely connected to their euphorigenic properties and their ability to suppress miserable feelings, hunger, and pain (Schmidbauer and von Scheidt 1977). The name morphine is derived from Morpheus, the greek god of dreams whose symbol is the opium poppy. The very name of this drug alludes to its trophic action on mental activity. Exogenous opioids act on receptors which are otherwise probably activated by endogenously produced opioid peptides. The use of exogenous opioids to mimic this endogenous system represents one of the first therapeutic exploitations of neuroendocrine circuits. Exogenous opioids may mirror (or represent an exaggeration of) the endogenus functions of opioids. It is therefore not surprising that endogenous opioid systems were ascribed a rewarding function. With this background, the discovery that some types of opioids elicit opposite, apparently unpleasant effects (Lasagna and Beecher 1954), was very exciting.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
eBook
USD 16.99
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 109.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  • Allen R, Young S (1978) Phencyclidine induced psychosis. Am J Psychiat 135: 1881–1883

    Google Scholar 

  • American Psychiatric Association (ed) (1980) Diagnostic and statistical manual of mental disorders, 3rd edn. APA, Washington DC

    Google Scholar 

  • Cohen BD, Rosenbaum G, Luby ED, Gottlieb JS (1962) Comparison of phencyclidine hydrochloride with other drugs. Arch Gen Psychiat 6: 395–403

    Article  PubMed  CAS  Google Scholar 

  • Cohen MR, Cohen RM, PickarD, WeingartnerH, Murphy DL, Bunney WEJr(1981) Behavioural effects after high dose naloxone administration to normal volunteers. Lancet ii:1110

    Google Scholar 

  • Domino EF, Chodoff P, Corrson G (1965) Pharmacologic effects of CI-581, a new dissociative anesthetic in man. Clin Pharm Ther 6: 279–291

    CAS  Google Scholar 

  • Haertzen CA (1970) Subjective effects of narcotic antagonists cyclazocine and nalorphine on the Addiction Research Center Inventory (ARCI). Psychopharmacologia 18: 366–377

    Article  PubMed  CAS  Google Scholar 

  • Hill E, Haertzen CA, Wolbach AB Jr, Miner EJ (1963) The Addiction Research Center Inventory: appendix. Psychopharmacology 4: 184–205

    Article  CAS  Google Scholar 

  • Jasinski DR (1977) Assessment of abuse potentiality of morphine-like drugs. Methods used in man. In: Martin WR (ed) Drug addiction, vol 1. Springer, Berlin Heidelberg New York, pp 198–258

    Google Scholar 

  • Jasinski DR (1979) Human pharmacology of narcotic antagonists. Br J Clin Pharm 7: 287S - 290S

    Google Scholar 

  • Jasinski DR, Martin WR, Sapira JD (1968) Antagonism of subjective, behavioural, pupillary and respiratory depressant effects of cyclazocine by naloxone. Clin Pharm Ther 9: 215–222

    CAS  Google Scholar 

  • Keats AS, Telford J (1964) Narcotic antagonists as analgesics. In: Godd RF (ed) Drug design, advances in chemistry, Ser 45 Am Chem Soc. Washington. pp 170–176

    Google Scholar 

  • Kumor KM, Haertzen CA, Johnsen RE, Kocher T, Jasinski D (1986) Human psychopharmacology of ketozyclazocine as compared with cyclazocine, morphine and placebo. J Pharmacol Exp Ther 238: 960–968

    PubMed  CAS  Google Scholar 

  • Lahti RA. Collins RJ (1982) Opiate effects on plasma corticosteroids: relationship to dysphoria and self-administration. Pharmacol Biochem Behav 17: 107–109

    Article  PubMed  CAS  Google Scholar 

  • Lasagna L. Beecher HK (1954) The analgesic effectiveness of nalorphine and nalorphine-morphine combinations in man. J Pharmacol Exp Ther 112: 356–363

    PubMed  CAS  Google Scholar 

  • Leander JD (1983) Further studies of kappa opioids on increased urination. J Pharmacol Exp Ther 227: 35–41

    PubMed  CAS  Google Scholar 

  • Lord JAH, Waterfield AA, Hughes J, Kosterlitz HW (1977) Endogenous opioid peptides: multiple agonists and receptors. Nature (London) 267: 495–499

    Article  CAS  Google Scholar 

  • Manallack DT, Beart PM, Gundlach AL (1986) Psychotomimetic sigma-opiates and PCP. Trends Pharmacol Sci 7: 448–451

    Article  CAS  Google Scholar 

  • Martin WR (1984) Pharmacology of opioids. Pharmacol Res 35: 283–345

    Google Scholar 

  • Martin WR. Gorodetsky CW (1965) Demonstration of tolerance and physical dependence on N- allylnormorphine (nalorphine). J Pharmacol Exp Ther 150: 437–442

    PubMed  CAS  Google Scholar 

  • Martin WR, Jasinski DR (1972) The mode of action and abuse potentiality of narcotic antagonists. In: Janzen R. Keidel WD. Herz A. Steichle C (eds) Pain. Thieme, Stuttgart. pp 225–234

    Google Scholar 

  • Martin WR. Sloan JW (1977) Pharmacology and classification of LSD-like hallucinogens. In: Martin WR (ed) Drug addiction. vol 2. Springer, Berlin Heidelberg New York, pp 305–354

    Google Scholar 

  • Martin WR, Fraser HF, Gorodetsky CW, Rosenberg DE (1965) Studies of the dependence producing potential of the narcotic antagonist cyclazocine. J Pharmacol Exp Ther 150: 426–436

    PubMed  CAS  Google Scholar 

  • Martin WR. Gorodetsky CW, McClane TK (1966) An experimental study in the treatment of narcotic addicts with naloxone. Clin Pharm Ther 7: 455–465

    CAS  Google Scholar 

  • Martin WR. Eades CG. Thompson WO, Huppler RE, Gilbert PE (1976) The effect of morphine and nalorphine-like drugs in the non-dependent and morphine-dependent chronic spinal dog. J Pharm Exp Ther 197: 517–532

    CAS  Google Scholar 

  • Martin WR, Eades CG, Gilbert PE, Thompson JA (1980) Tolerance and physical dependence on N-allylnormetazocine in chronic spinal dogs. Subst Alcohol Actions Misuse 1: 269–279

    PubMed  CAS  Google Scholar 

  • Maurer R, Cortes R. Probst A, Palacios JM (1983) Multiple opiate receptor in human brain: an autoradiographic study. Life Sci 33 (Suppl 1): 231–234

    Article  PubMed  CAS  Google Scholar 

  • Merz H, Stockhaus K (1979) N-(tetrahydrofuryl)alkyl and N-(alkoxyalkyl) derivatives of (—)normetazocine, compounds with differentiated opioid action profiles. J Med Chem 22: 1475–1479

    Article  PubMed  CAS  Google Scholar 

  • Merz H, Langbein A, Stockhaus K, Walther G, Wick H (1973) Structure activity relationships in narcotic antagonists with N-furylmethyl substituents. In: Braude MC (ed) Advances in biochemical pharmacology. vol 8: Narcotic antagonists. Raven, New York, pp 91–107

    Google Scholar 

  • Morris BJ, Herz A (1986) Autoradiographic distribution in rat brain of a non-conventional binding site for the opiate 3H-diprenorphine. Brain Res 384: 362–366

    Article  PubMed  CAS  Google Scholar 

  • Mucha RF, Herz A (1985) Motivational properties of kappa and mu opioid receptor agonists studied with place and taste preference conditioning. Psychopharmacology 86: 274–280

    Article  PubMed  CAS  Google Scholar 

  • Mucha RF, Milian MJ, Herz A (1985) Aversive properties of naloxone in non-dependent rats may involve blockade of central /3-endorphin. Psychopharmacology 86: 281–285

    Article  PubMed  CAS  Google Scholar 

  • Nutt JG, Jasinski DR (1974) Diuretic action of the narcotic antagonist oxilorphan. Clin Pharmacol Ther 15: 361–367

    PubMed  CAS  Google Scholar 

  • Peters GR. Ward NJ, Antal EG. Lai PY. DeMaar EW (1987) Diuretic actions in man of a selective kappa-opioid agonist: U-62,066E. J Pharmacol Exp Ther 240: 128–131

    PubMed  CAS  Google Scholar 

  • Pfeiffer A, Pasi A. Mehraein P, Herz A (1981) A subclassification of kappa-opiate sites in human brain by use of dynorphin 1–17. Neuropeptides 2: 89–97

    Article  CAS  Google Scholar 

  • Pfeiffer A. Pasi A, Mehraein P, Herz A (1982) Opiate receptor binding sites in human brain. Brain Res 248: 87–96

    Article  PubMed  CAS  Google Scholar 

  • Pfeiffer A, Feuerstein G, Kopin IJ, Faden AI (1983) Cardiovascular and respiratory effects of mu-, delta-and kappa-opiate agonists microinjected into the anterior hypothalamic brain area of awake rats. J Pharm Exp Ther 225: 735–741

    CAS  Google Scholar 

  • Pfeiffer A, Brand V, Herz A, Emrich HM (1986a) Psychotomimesis mediated by kappa-opiate receptors. Science 233: 774–776

    Article  PubMed  CAS  Google Scholar 

  • Pfeiffer A, Braun S, Mann K, Meyer H-D, Brantl V (1986b) Anterior pituitary hormone responses to a kappa-opioid agonist in man. J Clin Endocrinol Metab 62: 181–185

    Article  PubMed  CAS  Google Scholar 

  • Pfeiffer A, Knepel W, Braun S, Meyer HD, Lohmann H, Brantl V (1986c) Effects of a kappa-opioid agonist on adrenocorticotropic and diuretic function in man. Hormone Metab Res 18: 842–846

    Article  CAS  Google Scholar 

  • Quirion R, Chiceportiche R, Contreras PC, Johnson KM, Lodge D, Tam WS, Woods JH, Zukin SR (1987) Classification and nomenclature of pencyclidine and sigma receptor sites. TINS 10: 444–446

    CAS  Google Scholar 

  • Resnik RB, Fink M, Freedman AM (1971) Cyclazocine treatment of opiate dependence: a progress report. Compreh Psychiat 12: 491–502

    Article  Google Scholar 

  • Schmidbauer W, von Scheidt J (1977) Handbuch der Rauschdrogen. Fischer, Frankfurt, pp 294–306

    Google Scholar 

  • Shearman GT, Herz A (1982) Generalization and antagonism studies with rats trained to discriminate an effect of the proposed sigma opiate receptor agonist N-allylnormetazocine (SKF 10,047). In: Colpaert FC, Slangen JL (Eds) Drug discrimination: Application in CNS pharmacology. Elsevier, Amsterdam, pp 37–47

    Google Scholar 

  • Swain HH, Seevers MH (1974) Evaluation of new compounds for morphine-like physical dependence in the rhesus monkey. Bull Probl Drug Depend 36 Addendum 7: 11–68

    Google Scholar 

  • Szligi GR, Ludens JH (1982) Studies on the nature and mechanism of the diuretic action of the opioid analgesic ethylketocyclazocine. J Pharmacol Exp Ther 220: 585–591

    Google Scholar 

  • Szligi GR, Ludens JH (1985) Displacement of (3)H-EKC binding by opioids in rat kidney: a correlate to diuretic activity. Life Sci 36: 2189–2193

    Article  Google Scholar 

  • Szligi GR, Ludens JH (1986) Role of ADH in ethylketocyclazocine induced diuresis: studies in Brattleboro rats. Life Sci 38: 2437–2443

    Article  Google Scholar 

  • Tang AH (1985) Protection from cerebral schemia by U-50488H, a specific opiate analgesic agent. Life Sci 37: 1475–1482

    Article  PubMed  CAS  Google Scholar 

  • Tyers MB (1980) A classification of opiate receptors that mediate antinociception in animals. Br J Pharmacol 69: 503–508

    PubMed  CAS  Google Scholar 

  • Vaupel DB (1983) Phencyclidine does not interact with opioid receptors. Eur J Pharmacol 92:269–274 Vaupel DB, Risner ME, Shannon HE (1986) Pencyclidine and sigma-receptors. Drug Alcohol Depend 18: 173–194

    Google Scholar 

  • VonVoigtlander PF, Hall ED, Camacho-Ochoa M, Lewis RA, Triezenberg HJ (1987) U-55594A: a unique anticonvulsant related to kappa-opioid agonists. J Pharmacol Exp Ther 243: 542–547

    PubMed  CAS  Google Scholar 

  • Wood PL, Stotland M, Richard JW, Rackham A (1980) Actions of mu, kappa, sigma, delta and agonist/antagonist opiates on striatal dopaminergic function. J Pharmacol Exp Ther 215: 697–702

    PubMed  CAS  Google Scholar 

  • Woods JH, Smith CB, Medzihradsky F, Swain HH (1979) Preclinical testing of new analgesic drugs. In: Beers RF, Basset EG (Eds) Mechanisms of pain and analgesic compounds. Raven, New York, pp 429–445

    Google Scholar 

  • Zukin RS, Zukin SR (1981) Binding sites of cyclazocine. Mol Pharmacol 20: 246–254

    PubMed  CAS  Google Scholar 

Download references

Authors
  1. A. Pfeiffer
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Department of Neuroendocrinology, Max Planck Institute for Psychiatry, Kraepelinstraße 2, D-8000, München 40, Germany

    Osborne F. X. Almeida

  2. Department of Neuropharmacology, Max Planck Institute for Psychiatry, D-8033, Martinsried, Germany

    Toni S. Shippenberg

Rights and permissions

Reprints and permissions

Copyright information

© 1991 Springer-Verlag Berlin Heidelberg

About this chapter

Cite this chapter

Pfeiffer, A. (1991). Psychotomimetic Effects of Opioids. In: Almeida, O.F.X., Shippenberg, T.S. (eds) Neurobiology of Opioids. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-642-46660-1_21

Download citation

  • DOI: https://doi.org/10.1007/978-3-642-46660-1_21

  • Publisher Name: Springer, Berlin, Heidelberg

  • Print ISBN: 978-3-642-46662-5

  • Online ISBN: 978-3-642-46660-1

  • eBook Packages: Springer Book Archive

Publish with us

Policies and ethics

Search

Navigation